EGFR and cancer: For our glyco-engineered anti-PD-L1 antibody we found an enhanced NK cell-mediated ADCC against PD-L1+ cancer cells compared to the normal glycosylated variant, which is in line with the well-established superior ADCC capacity of several glyco-engineered antibodies (e.g., anti-CD20, anti-EGFR) (32, 35).